Nature Biotechnology, Published online: 05 August 2025; doi:10.1038/s41587-025-02778-7
Analogs of the pancreatic peptide hormone amylin are making strides in obesity as developers zoom in on oral drugs that can emulate or even improve on injectable GLP-1 agonists while avoiding muscle loss and gastrointestinal troubles.